(NEW YORK) -- A U.S. Food and Drug Administration analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.Rebound rates are around the same in people who took the drug and those... Read More.
(NEW YORK) -- Walgreens has launched a new delivery service for the COVID-19 oral antiviral therapy Paxlovid in partnership with DoorDash and Uber to get the treatment "directly to the doorsteps of those who need it."Walgreens on Thursday said it has more than 8,000... Read More.
(NEW YORK) -- Six months ago, Dr. Joseph Boselli said he was prescribing the antiviral drug Paxlovid to nearly everyone who turned up at his practice with COVID.Now, the internal medicine physician at Jefferson Health in Philadelphia said he's reserving it mostly for people... Read More.
(NEW YORK) -- When White House officials announced President Joe Biden tested positive for COVID-19 Thursday, they revealed he was prescribed Paxlovid.Here's what to know about the COVID-19 treatment:Paxlovid is an at-home antiviral therapy developed by Pfizer, which was authorized under emergency use by... Read More.
(NEW YORK) -- After testing positive for COVID-19 earlier this month, Dr. Anthony Fauci said Tuesday that he has joined a growing group of people experiencing a Paxlovid rebound, following treatment with Pfizer's antiviral.Fauci, 81, said that when he first tested positive two weeks... Read More.
(WASHINGTON) -- Pfizer's COVID-19 treatment Paxlovid has been hailed as a breakthrough in the fight against COVID-19. The pills have shown to dramatically reduce the risk of being hospitalized or dying for people who are at high-risk of COVID-19.But mounting evidence suggests Paxlovid may... Read More.
(NEW YORK) -- When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer.Just one day after her diagnosis, she started her five-day course of pills, which have... Read More.